Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | HTR1D | P28221 | 5/20 | 0.40 |
| ▸ | HTR1B | P28222 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | HTR5A | P47898 | 2/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR1E | P28566 | 1/20 | 0.36 |
| ▸ | HTR1F | P30939 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139242 | 0.83 | CA1 (0.35) | ALDH1A1HTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL13209743 | 0.82 | CYP1A2 (0.47) | MEN1POLBKMT2ANCF1CYP1A2 | |
| SCHEMBL426939 | 0.82 | RAF1 (0.36) | MEN1KMT2AHTR1DDRD2DRD4 | |
| SCHEMBL4175720 | 0.80 | LMNA (0.42) | ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL3580521 | 0.79 | MEN1 (0.48) | MEN1KMT2ACYP1A2 | |
| SCHEMBL3580231 | 0.79 | DRD2 (0.36) | HTR1DDRD2DRD4DRD3HTR5A | |
| SCHEMBL15673030 | 0.78 | CNR2 (0.36) | HTR1DDRD2DRD4DRD3HTR5A | |
| SCHEMBL481371 | 0.78 | CLK1 (0.42) | POLBNR3C1 | |
| SCHEMBL2880729 | 0.77 | CYBB (0.33) | KMT2AHTR1AHTR1DHTR1BDRD2 | |
| SCHEMBL203899 | 0.77 | MEN1 (0.42) | MEN1KMT2AHTR1DDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| CN-101048414-B | Fused tricyclic derivatives for the treatment of psychotic disorders | GLAXO GROUP LTD | 2011-09-07 | — | — | CN | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| US-7964603-B2 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-21 | — | — | US | disclosed |
| EP-2016943-B1 | Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2011-02-23 | — | — | EP | disclosed |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2007-07-19 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| CN-1852896-A | Quinoline and quinazoline derivatives having affinity for 5HT 1-type receptors | GLAXO GROUP LTD (GB) | 2006-10-25 | — | — | CN | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1646613-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | ALDH1A1 2366/4885MEN1 3652/4885POLB 2664/4885 |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | ALDH1A1 257/4885MEN1 4304/4885POLB 1588/4885 |
| US-20070167423-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | ALDH1A1 1826/4885MEN1 692/4885POLB 3053/4885 |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | ALDH1A1 313/4885MEN1 2472/4885POLB 3219/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | ALDH1A1 1826/4885MEN1 692/4885POLB 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.